v3.25.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Apr. 21, 2025
Jun. 28, 2024
Document Information [Line Items]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Central Index Key 0001479615    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag true    
Amendment Description EXPLANATORY NOTESilence Therapeutics plc (the “Company,” “Silence,” “we,” “us” or “our”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend our Annual Report on Form 10-K for the year ended December 31, 2024, originally filed with the Securities and Exchange Commission (the “SEC”) on February 27, 2025 (the “Original 10-K”), to (i) include the information required by Items 10 through 14 of Part III of Form 10-K and (ii) amend Item 15 of Part IV of the Original 10-K to update the exhibit list. The information required by Items 10 through 14 of Part III of Form 10-K was previously omitted from the Original 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K by reference from our definitive proxy statement if such statement is filed no later than 120 days after our fiscal year-end. We are filing this Amendment to include Part III information in our Form 10-K because a definitive proxy statement containing such information may not be filed by Silence within 120 days after the end of the fiscal year covered by the Form 10-K.In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Part III, Items 10 through 14 of the Original 10-K are hereby amended and restated in their entirety. Additionally, in accordance with Rules 12b-15 and 13a-14 under the Exchange Act, we have amended Part IV, Item 15 to include currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Since no new financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, since no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.Except for the changes to Part III and Item 15 of Part IV, including the filing of related certifications added to the exhibit list in Part IV, this Amendment makes no changes to the Original 10-K. This Amendment does not reflect events occurring after the filing of the Original 10-K or modify disclosures affected by subsequent events. Terms used but not otherwise defined in this Amendment have such meaning as ascribed to them in the Original 10-K.    
Document Transition Report false    
Entity File Number 001-39487    
Entity Registrant Name Silence Therapeutics plc    
Entity Incorporation, State or Country Code X0    
Entity Tax Identification Number 00-0000000    
Entity Address, Address Line One 72 Hammersmith Road    
Entity Address, City or Town London    
Entity Address, Country GB    
Entity Address, Postal Zip Code W14 8TH    
City Area Code +44 20    
Local Phone Number 3457 6900    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 737.9
Entity Common Stock, Shares Outstanding   141,690,850  
Documents Incorporated by Reference [Text Block]

DOCUMENTS INCORPORATED BY REFERENCE

None.

    
Auditor Name PricewaterhouseCoopers LLP    
Auditor Location London, United Kingdom    
Auditor Firm ID 876    
American Depositary Shares      
Document Information [Line Items]      
Title of 12(b) Security American Depositary Shares, each representing three ordinaryshares, nominal value £0.05 per share    
Trading Symbol SLN    
Security Exchange Name NASDAQ    
Ordinary Shares      
Document Information [Line Items]      
Title of 12(b) Security Ordinary share, nominal value £0.05 per share    
No Trading Symbol Flag true    
Security Exchange Name [1] NASDAQ    
[1] Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.